EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeit

Overlapping autoimmunity and demyelination syndromes associated with TNF inhibitor therapy

Rula Daood, Mohammad E Naffaa, Olga Azrilin, Fadi Hassan, Helana Jeries, Putterman Chaim

Clinical Rheumatology · 2026

DOI: 10.1007/s10067-026-07976-5 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Rheumatology, 2026. Verfasst von Rula Daood und 5 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Unit, Galilee Medical Center, Nahariya, Israel. rula.daood@gmail.com. Hauptthemen laut MEDLINE: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Adalimumab, Spondylitis, Ankylosing, Lupus Erythematosus, Systemic. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a demyelinating disorder of the central nervous system. We describe a case of a 31-year-old male with ankylosing spondylitis who developed optic neuritis and transverse myelitis accompanied by positive anti-MOG antibodies, and subsequently features consistent with systemic lupus erythematosus (SLE), beginning 3 months after initiating adalimumab. Adalimumab was discontinued, and the patient was treated with pulsed intravenous methylprednisolone followed by rituximab with significant improvement in clinical, imaging, and laboratory manifestations of the disease. This case highlights a rare constellation of overlapping autoimmune diseases, with both MOGAD and SLE emerging after anti-TNF antibody exposure in a patient with ankylosing spondylitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseAdalimumabSpondylitis, AnkylosingLupus Erythematosus, SystemicDemyelinating DiseasesAutoimmunityTumor Necrosis Factor InhibitorsHumansMaleAdultRituximabMyelin-Oligodendrocyte GlycoproteinOptic NeuritisMethylprednisoloneMyelitis, TransverseTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

Ankylosing spondylitisMyelin oligodendrocyte glycoprotein antibody-associated diseaseSystemic lupus erythematosus

Substanzen

AdalimumabRituximabMyelin-Oligodendrocyte GlycoproteinMethylprednisoloneTumor Necrosis Factor InhibitorsTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Rheumatology Unit, Galilee Medical Center, Nahariya, Israel. rula.daood@gmail.com.
  • Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel. rula.daood@gmail.com.
  • Rheumatology Unit, Galilee Medical Center, Nahariya, Israel.
  • Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
  • Neurology Department, Galilee Medical Center, Nahariya, Israel.

Zitieren

APA

Daood, R., Naffaa, M. E., Azrilin, O., Hassan, F., Jeries, H., & Chaim, P. (2026). Overlapping autoimmunity and demyelination syndromes associated with TNF inhibitor therapy. Clinical Rheumatology. https://doi.org/10.1007/s10067-026-07976-5

Vancouver

Daood R, Naffaa ME, Azrilin O, Hassan F, Jeries H, Chaim P. Overlapping autoimmunity and demyelination syndromes associated with TNF inhibitor therapy. Clinical Rheumatology. 2026. doi:10.1007/s10067-026-07976-5

BibTeX
@article{Daood2026,
  author = {Daood, Rula and Naffaa, Mohammad E and Azrilin, Olga and Hassan, Fadi and Jeries, Helana and Chaim, Putterman},
  title = {Overlapping autoimmunity and demyelination syndromes associated with TNF inhibitor therapy},
  journal = {Clinical Rheumatology},
  year = {2026},
  doi = {10.1007/s10067-026-07976-5}
}
Kostenlos starten →